NCT01812954: Economic Evaluation of Systemic Treatments for Moderate-to-severe Psoriasis |
|
|
| Completed | N/A | 1 | NA | Methotrexate, Cyclosporins, fumaric acid, Acitretin, Infliximab, etanercept, Adalimumab, Ustekinumab | Jochen Schmitt., Merck Sharp & Dohme LLC | Psoriasis | 06/14 | 06/14 | | |
